Faculty

Samer Al Hadidi

MD
Clinical Director of Amyloidosis Program
UT Southwestern Medical Center

Samer Al Hadidi, M.D., M.S., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center. He specializes in hematology and oncology, with an emphasis on plasma cell disorders, including multiple myeloma and light chain amyloidosis, and cellular therapies, including CAR T-cell therapy and hematopoietic stem cell transplantation.

Dr. Al Hadidi earned his medical degree at the University of Jordan School of Medicine. He completed a residency in internal medicine at Hurley Medical Center/Michigan State University. He received advanced training through a hematology and oncology fellowship at Baylor College of Medicine in Houston. He also holds a master’s degree in clinical research and statistical analysis from the University of Michigan in Ann Arbor.

Dr. Al Hadidi is the Clinical Director of the Amyloidosis Program at UT Southwestern. He also serves as Leader of the Fellows’ Plasma Cell Disorders Clinic. He is nationally recognized as an expert in treating multiple myeloma and utilizing cellular therapies for plasma cell disorders.Dr. Al Hadidi serves on the Hematology Specialty Board of the American Board of Internal Medicine, helping to oversee certification standards, specialty assessment, and governance policies for hematology.

Dr. Al Hadidi has delivered national and international presentations and published more than 140 peer-reviewed academic articles related to his areas of expertise.

2026 Sessions

Defining the Default: Should Daratumumab Be Used Up Front in High-Risk Smoldering Myeloma?

  • Debate Speaker
    • Samer Al Hadidi
    • Shaji Kumar

Watch & Wait

  • Debate Speaker
    • Samer Al Hadidi

Question & Answer Panel

  • Debate Speaker
    • Shaji Kumar
    • Samer Al Hadidi
  • Moderator
    • Joseph Mikhael

Fresh Data, Fast Impact: Myeloma Updates

  • Moderator
    • Joseph Mikhael
  • Panelist
    • Saad Usmani
    • Shaji Kumar
    • Samer Al Hadidi

Defining the Default: Should Daratumumab Be Used Up Front in High-Risk Smoldering Myeloma?

  • Debate Speaker
    • Shaji Kumar
    • Samer Al Hadidi

Watch & Wait

  • Debate Speaker
    • Samer Al Hadidi

Question & Answer Panel

  • Panelist
    • Shaji Kumar
    • Samer Al Hadidi
  • Moderator
    • Joseph Mikhael

Fresh Data, Fast Impact: Myeloma Updates

  • Moderator
    • Shaji Kumar
  • Panelist
    • Krina Patel
    • Prashant Kapoor
    • Samer Al Hadidi
    • Jonathan Kaufman
Back to top